Germany Pulmonary Arterial Hypertension Market Size & Outlook
Germany pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Germany pulmonary arterial hypertension market highlights
- The Germany pulmonary arterial hypertension market generated a revenue of USD 469.2 million in 2023 and is expected to reach USD 635.7 million by 2030.
- The Germany market is expected to grow at a CAGR of 4.4% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 469.2 million |
| Market revenue in 2030 | USD 635.7 million |
| Growth rate | 4.4% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Germany accounted for 6.4% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 46.97% in 2023. Horizon Databook has segmented the Germany pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Germany held the lion’s share during the forecast period. Amongst many causes for development of PAH smoking, obesity, diabetes and high level of cholesterol increase the PAH risk highest, other causes include aging and genetic reasons.
With the oldest national social health insurance system, German healthcare system is considered as the pioneering one in public health support. Moreover, schemes such as “Statutory Health Insurance” are strengthening healthcare infrastructure, thus facilitating people to undergo.
Germany’s population is rapidly aging, with a gradual increase in the prevalence of rare disorders, which is likely to support market growth. According to an article published in 2014, in the country, almost 4 million people are affected by a rare disorder. The German Federal Ministry of Health (BMG) has taken actions to create awareness about the treatment options available for rare diseases.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Germany Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
